CN110144008B - Cd38蛋白抗体及其应用 - Google Patents

Cd38蛋白抗体及其应用 Download PDF

Info

Publication number
CN110144008B
CN110144008B CN201810144817.4A CN201810144817A CN110144008B CN 110144008 B CN110144008 B CN 110144008B CN 201810144817 A CN201810144817 A CN 201810144817A CN 110144008 B CN110144008 B CN 110144008B
Authority
CN
China
Prior art keywords
antibody
antigen
amino acid
acid sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810144817.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN110144008A (zh
Inventor
吕明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Sumgen Biotech Co Ltd
Sumgen MAb Beijing Biotech Co Ltd
Original Assignee
Hangzhou Sumgen Biotech Co Ltd
Sumgen MAb Beijing Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201810144817.4A priority Critical patent/CN110144008B/zh
Application filed by Hangzhou Sumgen Biotech Co Ltd, Sumgen MAb Beijing Biotech Co Ltd filed Critical Hangzhou Sumgen Biotech Co Ltd
Priority to RU2020129820A priority patent/RU2776795C2/ru
Priority to AU2019218518A priority patent/AU2019218518B2/en
Priority to KR1020207026216A priority patent/KR102770962B1/ko
Priority to CA3091492A priority patent/CA3091492C/en
Priority to TW108104450A priority patent/TWI818952B/zh
Priority to JP2020565006A priority patent/JP7333523B2/ja
Priority to US16/968,994 priority patent/US11713357B2/en
Priority to SG11202007443XA priority patent/SG11202007443XA/en
Priority to CN202210259987.3A priority patent/CN114835809A/zh
Priority to CN201980012880.5A priority patent/CN111712521B/zh
Priority to BR112020016271-0A priority patent/BR112020016271A2/pt
Priority to PCT/CN2019/074806 priority patent/WO2019154421A1/zh
Priority to EP19751277.5A priority patent/EP3753955A4/en
Publication of CN110144008A publication Critical patent/CN110144008A/zh
Application granted granted Critical
Publication of CN110144008B publication Critical patent/CN110144008B/zh
Priority to US18/176,972 priority patent/US20230250186A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201810144817.4A 2018-02-12 2018-02-12 Cd38蛋白抗体及其应用 Active CN110144008B (zh)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CN201810144817.4A CN110144008B (zh) 2018-02-12 2018-02-12 Cd38蛋白抗体及其应用
CN201980012880.5A CN111712521B (zh) 2018-02-12 2019-02-11 Cd38蛋白抗体及其应用
KR1020207026216A KR102770962B1 (ko) 2018-02-12 2019-02-11 Cd38 단백질 항체 및 이의 용도
CA3091492A CA3091492C (en) 2018-02-12 2019-02-11 Cd38 protein antibody and application thereof
TW108104450A TWI818952B (zh) 2018-02-12 2019-02-11 Ｃｄ３８蛋白抗體及其應用
JP2020565006A JP7333523B2 (ja) 2018-02-12 2019-02-11 Ｃｄ３８タンパク質抗体及びその使用
US16/968,994 US11713357B2 (en) 2018-02-12 2019-02-11 CD38 protein antibody and application thereof
SG11202007443XA SG11202007443XA (en) 2018-02-12 2019-02-11 Cd38 protein antibody and application thereof
RU2020129820A RU2776795C2 (ru) 2018-02-12 2019-02-11 Антитела к белку cd38 и их применение
AU2019218518A AU2019218518B2 (en) 2018-02-12 2019-02-11 CD38 protein antibody and application thereof
BR112020016271-0A BR112020016271A2 (pt) 2018-02-12 2019-02-11 Anticorpo da proteína cd38 e aplicação do mesmo
PCT/CN2019/074806 WO2019154421A1 (zh) 2018-02-12 2019-02-11 Cd38蛋白抗体及其应用
EP19751277.5A EP3753955A4 (en) 2018-02-12 2019-02-11 CD38 PROTEIN ANTIBODIES AND ASSOCIATED USE
CN202210259987.3A CN114835809A (zh) 2018-02-12 2019-02-11 Cd38蛋白抗体及其应用
US18/176,972 US20230250186A1 (en) 2018-02-12 2023-03-01 Cd38 protein antibody and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810144817.4A CN110144008B (zh) 2018-02-12 2018-02-12 Cd38蛋白抗体及其应用

Publications (2)

Publication Number Publication Date
CN110144008A CN110144008A (zh) 2019-08-20
CN110144008B true CN110144008B (zh) 2021-03-19

Family

ID=67547850

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201810144817.4A Active CN110144008B (zh) 2018-02-12 2018-02-12 Cd38蛋白抗体及其应用
CN201980012880.5A Active CN111712521B (zh) 2018-02-12 2019-02-11 Cd38蛋白抗体及其应用
CN202210259987.3A Pending CN114835809A (zh) 2018-02-12 2019-02-11 Cd38蛋白抗体及其应用

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201980012880.5A Active CN111712521B (zh) 2018-02-12 2019-02-11 Cd38蛋白抗体及其应用
CN202210259987.3A Pending CN114835809A (zh) 2018-02-12 2019-02-11 Cd38蛋白抗体及其应用

Country Status (11)

Country Link
US (1) US11713357B2 (enExample)
EP (1) EP3753955A4 (enExample)
JP (1) JP7333523B2 (enExample)
KR (1) KR102770962B1 (enExample)
CN (3) CN110144008B (enExample)
AU (1) AU2019218518B2 (enExample)
BR (1) BR112020016271A2 (enExample)
CA (1) CA3091492C (enExample)
SG (1) SG11202007443XA (enExample)
TW (1) TWI818952B (enExample)
WO (1) WO2019154421A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303293B (zh) * 2018-11-14 2022-08-30 杭州尚健生物技术有限公司 一种融合蛋白及其用途
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
CN114075283A (zh) * 2020-08-12 2022-02-22 三生国健药业（上海）股份有限公司 结合人cd38的抗体、其制备方法和用途
CN114075285B (zh) * 2020-08-20 2023-05-30 瑞阳(苏州)生物科技有限公司 抗人cd38人源化单克隆抗体及其应用
CN116547307A (zh) * 2021-12-03 2023-08-04 南京维立志博生物科技有限公司 结合cd38的抗体及其用途
WO2024183634A1 (en) * 2023-03-09 2024-09-12 Norroy Bioscience Co., Ltd. Radiolabeled antibody conjugates and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP2915820A1 (en) 2004-02-06 2015-09-09 MorphoSys AG Anti-CD38 human antibodies and uses therefor
RU2402568C2 (ru) 2004-02-06 2010-10-27 МорфоСис АГ Человеческие анти-cd38-антитела и их применение
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2342220B1 (en) * 2008-10-06 2021-05-12 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US10533057B2 (en) 2015-05-13 2020-01-14 Morphosys Ag Treatment for multiple myeloma (MM)
CR20170526A (es) * 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
JP7027321B2 (ja) * 2015-11-03 2022-03-01 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下製剤及びその使用
KR102770106B1 (ko) * 2017-06-08 2025-02-21 블랙 벨트 테라퓨틱스 리미티드 Cd38 조정 항체
US11780930B2 (en) 2017-06-08 2023-10-10 Black Belt Therapeutics Limited CD38 modulating antibody

Also Published As

Publication number Publication date
KR102770962B1 (ko) 2025-02-24
US11713357B2 (en) 2023-08-01
WO2019154421A1 (zh) 2019-08-15
JP2021512652A (ja) 2021-05-20
RU2020129820A (ru) 2022-03-14
KR20200120937A (ko) 2020-10-22
BR112020016271A2 (pt) 2020-12-15
RU2020129820A3 (enExample) 2022-03-14
JP7333523B2 (ja) 2023-08-25
SG11202007443XA (en) 2020-09-29
US20210024645A1 (en) 2021-01-28
AU2019218518B2 (en) 2025-07-10
CN114835809A (zh) 2022-08-02
EP3753955A1 (en) 2020-12-23
CN111712521B (zh) 2022-03-15
EP3753955A4 (en) 2021-12-08
AU2019218518A1 (en) 2020-10-01
CA3091492A1 (en) 2019-08-15
TWI818952B (zh) 2023-10-21
CA3091492C (en) 2023-10-10
CN111712521A (zh) 2020-09-25
TW201934577A (zh) 2019-09-01
CN110144008A (zh) 2019-08-20

Similar Documents

Publication Publication Date Title
AU2019228474B2 (en) PD-1 agonist antibodies and uses thereof
KR102770962B1 (ko) Cd38 단백질 항체 및 이의 용도
KR101439719B1 (ko) Ｃｓｆ-１ｒ에 대한 항체
CN110545844A (zh) 使用结合细胞毒性t淋巴细胞抗原-4(ctla-4)的抗体的癌症治疗
CN110540592B (zh) 结合axl蛋白的抗体及其应用
TW201011045A (en) Anti-CD5 antibodies
KR20100113589A (ko) 폰 빌레브란트 인자에 특이적인 인간화 항체
KR20100097684A (ko) Ａｘｌ 항체
KR20140107507A (ko) 신규 항 인간 ctgf 항체
RU2776795C2 (ru) Антитела к белку cd38 и их применение
HK40006534A (en) Cd38 protein antibody and its application
HK40006534B (zh) Cd38蛋白抗体及其应用
US20230250186A1 (en) Cd38 protein antibody and application thereof
HK40013210A (en) Antibody binding to axl protein and application thereof
HK40013210B (en) Antibody binding to axl protein and application thereof
CN115181180A (zh) 抗人程序性死亡配体-1（pd-l1）的抗体及其应用
HK40029523B (en) Cd38 protein antibody and application thereof
HK40029523A (en) Cd38 protein antibody and application thereof
HK40034156A (en) Cd38 protein antibody and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40006534

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: 310056 Zhejiang Province, Hangzhou City, China (Zhejiang) Pilot Free Trade Zone, Binjiang District, Changhe Street, Bin'an Road 688, Building 2, C Floor, 1st Floor

Patentee after: Hangzhou Shangjian Biotechnology Co.,Ltd.

Country or region after: China

Patentee after: SUMGEN MAB (BEIJING) BIOTECH Co.,Ltd.

Address before: 310051-005, 3 / F, huannuo building, 1568 South Ring Road, Changhe street, Binjiang District, Hangzhou City, Zhejiang Province

Patentee before: HANGZHOU SUMGEN BIOTECH Co.,Ltd.

Country or region before: China

Patentee before: SUMGEN MAB (BEIJING) BIOTECH Co.,Ltd.